Pro-Thrombin Concentrate Complex — Competitive Intelligence Brief

Pro-Thrombin Concentrate Complex (Pro-Thrombin Concentrate Complex) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Clotting factor concentrate. Area: Hematology.

phase 3 Clotting factor concentrate Coagulation factors II, VII, IX, X Hematology Small molecule

Target snapshot

Pro-Thrombin Concentrate Complex (Pro-Thrombin Concentrate Complex) — University Hospital, Grenoble. Prothrombin Complex Concentrate (PCC) replaces deficient vitamin K-dependent clotting factors (II, VII, IX, X) to restore coagulation cascade function.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pro-Thrombin Concentrate Complex TARGET	Pro-Thrombin Concentrate Complex	University Hospital, Grenoble	phase 3	Clotting factor concentrate	Coagulation factors II, VII, IX, X
Prothrombin complex	Prothrombin complex	IRCCS Policlinico S. Donato	marketed	Vitamin K-dependent clotting factor concentrate	Coagulation factors II, VII, IX, X
Factor Concentrate (Bebulin)	Factor Concentrate (Bebulin)	The University of Texas Health Science Center, Houston	marketed	Prothrombin complex concentrate (PCC)	Coagulation factors II, VII, IX, X
Alphanate SD/HT	Alphanate SD/HT	Grifols Biologicals, LLC	marketed	Clotting factor concentrate; Factor VIII replacement therapy	Factor VIII (antihemophilic factor)
Traditional Cryoprecipitate	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Clotting factor concentrate class)

1. University Hospital, Grenoble · 1 drug in this class